Latest Breaking News On - Alessio ciulli - Page 7 : comparemela.com

Amphista Therapeutics Expands Research Team by Appointing Martin O Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry

Amphista Therapeutics Expands Research Team by Appointing Martin O Rourke as Head of Drug Discovery and James Osborne as Director of Chemistry
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Glasgow cityUnited kingdomAlessio ciulliIan churcherTracy robsonMartin orourkeQueen university belfastEli lilly companyUniversity of ulsterUniversity of oxfordAdvent life sciencesAstex pharmaceuticalsNottingham universityGw pharmaceuticalsScius communicationsInstitute of cancer research

Protein Degradation Centre to Revolutionise Drug Discovery

Protein Degradation Centre to Revolutionise Drug Discovery
labmate-online.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from labmate-online.com Daily Mail and Mail on Sunday newspapers.

Alessio ciulliWilliam farnabyCentre for targeted protein degradationDundee school of life sciencesCentre for targeted protein degradation ceUniversity of dundeeTargeted protein degradationLife sciencesProfessor alessio ciulliTay cities regional innovationTay cities dealடண்டீ பள்ளி ஆஃப் வாழ்க்கை அறிவியல்பல்கலைக்கழகம் ஆஃப் டண்டீவாழ்க்கை அறிவியல்தாய் நகரங்கள் ஒப்பந்தம்

University of Dundee announces £5m research centre to create 25 jobs

University of Dundee announces £5m research centre to create 25 jobs
thecourier.co.uk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from thecourier.co.uk Daily Mail and Mail on Sunday newspapers.

Alessio ciulliIain gillespieCentre for targeted protein degradationCourtesy dundee university professor iain gillespieDundee school of life sciencesUniversity of dundee artistCentre for targeted protein degradation ceUniversity of dundeeTargeted proteinTargeted protein degradationProfessor alessio ciulliProfessor ciulliCities dealTay cities regional innovationTay cities dealCourtesy dundee university

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets

Amphista Therapeutics raises $53M in oversubscribed Series B round to advance next generation targeted protein degradation assets About Amphista Therapeutics Amphista Therapeutics is a biopharmaceutical company creating first-in-class therapeutics that harness the body s natural processes to selectively and efficiently degrade and remove disease-causing proteins. The company s pipeline of novel targeted protein degradation (TPD) based medicines is focused on challenging diseases including cancer. Founded by Advent Life Sciences, Amphista is a spin-out of TPD expert Professor Alessio Ciulli s labs at the University of Dundee. The company has raised approximately £45M to date and is funded by leading life science investors including Forbion, Gilde Healthcare, Novartis Venture Fund, Advent Life Sciences, BioMotiv and Eli Lilly and Company.

Glasgow cityUnited kingdomUnited statesAlessio ciulliRogier rooswinkelKostenloser wertpapierhandelFlorian muellershausenStefan luziNicola thompsonEli lillyAdvent life sciencesEuropean recovery programmeScius communicationsHarrington project for discovery developmentDutch venture initiativeNovartis venture fund